Aspen Investment Fund is considering a nonbinding offer worth $640 million for Vivus, potentially starting a new battle for control of the pharmaceutical firm.
from WSJ.com: US Business http://ift.tt/1mF9PhV
via IFTTT
from WSJ.com: US Business http://ift.tt/1mF9PhV
via IFTTT
No comments:
Post a Comment